Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.
Adverse drug event
Colitis
Diagnostic imaging
Neoplasms
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
23
11
2019
medline:
21
5
2021
entrez:
23
11
2019
Statut:
ppublish
Résumé
To determine the frequency, imaging, and clinical manifestations of immune checkpoint inhibitor (ICI)-related colitis in cancer patients on monotherapy or combination therapy. The electronic medical records of 1044 cancer patients who received ICIs were retrospectively reviewed to identify 48 patients who had a clinical diagnosis of immune-related colitis. Imaging studies were reviewed to identify patients with imaging manifestations of colitis. Demographic data, type of ICIs, symptoms, presence of other immune-related adverse events (irAEs), and management were recorded. There was imaging evidence of immune-related colitis in 34 patients (24 men; median age: 63.5 years). The median time to onset of colitis was 75 days (IQR 25-75, 49.5-216 days) in patients receiving monotherapy (group 1) and 78 days (IQR 25-75, 44.3-99.5 days) in patients undergoing combination therapy (group 2) following start of ICI. Symptoms included diarrhea (91.1% [31 of 34]), nausea/vomiting (52.9% [18 of 34]), and abdominal pain (52.9% [18 of 34]). The most common imaging findings were bowel wall thickening (97% [33 of 34]) and fluid-filled colon (82.3% [28 of 34]). Colitis was diffuse in 21 of 34 (61.8%) patients. Imaging manifestations did not differ between the two groups (p > 0.05). Steroids and antibiotics were used to treat colitis in 29 of 34 (85.2%) and 13 of 34 (38.2%) patients, respectively. No patients in group 1 experienced concurrent irAEs, but 5 of 18 (27.8%) of patients in group 2 had other irAEs (p = 0.046). Immune-related colitis occurred in 3.3% of patients receiving ICIs with bowel wall thickening, fluid-filled colon and pancolitis being the most common imaging manifestations. Imaging manifestations did not differ between patients receiving monotherapy or combination therapy. However, concurrent irAEs were significantly observed in patients undergoing combination therapy.
Identifiants
pubmed: 31754740
doi: 10.1007/s00261-019-02334-3
pii: 10.1007/s00261-019-02334-3
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3028-3035Références
Press Announcements > FDA approves new treatment for a type of late-stage skin cancer. https://web.archive.org/web/20110327063147/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm1193237.htm . Published March 27, 2011. Accessed June 2, 2019.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 377:1345-1356.
doi: 10.1056/NEJMoa1709684
Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M (2015) Radiographic Profiling of Immune-related Adverse Events in Advanced Melanoma Patients Treated With Ipilimumab. Cancer Immunol Res 3:1185-1192.
doi: 10.1158/2326-6066.CIR-15-0102
Puzanov I, Diab A, Abdallah K, et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95.
doi: 10.1186/s40425-017-0300-z
Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, Ibrahim N (2013) Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 200:W468-474.
doi: 10.2214/AJR.12.9751
Mekki A, Dercle L, Lichtenstein P, et al (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91-104.
doi: 10.1016/j.ejca.2018.03.006
Beck KE, Blansfield JA, Tran KQ, et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283-2289.
doi: 10.1200/JCO.2005.04.5716
Weber J, Thompson JA, Hamid O, et al (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598.
doi: 10.1158/1078-0432.CCR-09-1024
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 28(suppl 4):iv119-iv142.
Sosa A, Cadena EL, Olive CS, Karachaliou N, Rosell R (2018) Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 10:1758835918764628.
doi: 10.1177/1758835918764628
Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2:1346-1353.
doi: 10.1001/jamaoncol.2016.1051
Gupta A, De Felice KM, Loftus EV Jr, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42:406-417.
doi: 10.1111/apt.13281
Garcia-Neuer M, Marmarelis ME, Jangi SR, et al (2017) Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. Cancer Immunol Res 5:286-291.
doi: 10.1158/2326-6066.CIR-16-0302
Wang DY, Ye F, Zhao S, Johnson DB (2017) Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 6:e1344805.
doi: 10.1080/2162402X.2017.1344805
Horn L, Spigel DR, Vokes EE, et al (2017) Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small- Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924-3933.
doi: 10.1200/JCO.2017.74.3062
Alessandrino F, Sahu S, Nishino M, et al (2019) Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol (NY) 44:1917-1927.
doi: 10.1007/s00261-019-01935-2
Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med 373:1270-1271.
doi: 10.1056/NEJMoa1504030
Irwin DE, Davis B, Bell JA, Galaznik A, Garcia-Ribas I (2018) Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. J Comp Eff Res 8:81-90.
doi: 10.2217/cer-2018-0072
Reddy HG, Schneider BJ, Tai AW (2018) Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clin Transl Gastroenterol 9:180.
doi: 10.1038/s41424-018-0049-9
Zhou S, Khanal S, Zhang H (2019) Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag 15:211-221.
doi: 10.2147/TCRM.S193338